# EDGAR Filing Document

**Accession Number:** 0001935979
**File Stem:** 0001935979-26-000042
**Filing Date:** 2026-5
**Character Count:** 5487
**Document Hash:** 7559212f666104afd4dbccce35416e2d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001935979-26-000042.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0001935979-26-000042

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260428

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biohaven Ltd.
- **CENTRAL INDEX KEY:** 0001935979
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41477
- **FILM NUMBER:** 26937347

**BUSINESS ADDRESS:**
- **STREET 1:** 215 CHURCH STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06510
- **BUSINESS PHONE:** 203-404-0410

**MAIL ADDRESS:**
- **STREET 1:** 215 CHURCH STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06510

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biohaven Research Ltd.
- **DATE OF NAME CHANGE:** 20220629

?xml version='1.0' encoding='ASCII'? bhvn-20260428

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of** 

**The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 28, 2026

**Biohaven Ltd.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **British Virgin Islands** | **001-41477** | **Not applicable** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**c/o Biohaven Pharmaceuticals, Inc.**

**215 Church Street**

**New Haven, Connecticut 06510**

(Address of principal executive offices, including zip code)

**(203) 404-0410**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading symbol Name of each exchange on which registered <br> <u>Common Shares, no par value</u> <u>BHVN</u> <u>New York Stock Exchange</u>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On April 28, 2026, Biohaven Ltd. (the "Company") held its 2026 annual meeting of shareholders (the "Annual Meeting").

Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting.

<u>Proposal No. 1</u>: Election of directors for a term expiring at the 2029 Annual Meeting of Shareholders.

---

| | | | |
|:---|:---|:---|:---|
| | **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Abstained</u>** |
| Proposal No. 1(a): Michael T. Heffernan | 76,133,746 | 15,092,665 | 1,984,918 |
| Proposal No. 1(b): Irina Antonijevic, M.D., Ph.D. | 76,612,017 | 14,616,115 | 1,983,197 |
| Proposal No. 1(c): Robert J. Hugin | 76,597,707 | 14,626,151 | 1,987,471 |

---

Broker Non-Votes: 32,137,064

All nominees were elected.

<u>Proposal No. 2</u>: Ratification of the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026.

---

| | | | |
|:---|:---|:---|:---|
| | **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Abstained</u>** |
| Ratification of appointment of Ernst & Young LLP | 123,723,636 | 214,123 | 1,410,634 |

---

Broker Non-Votes: 0

Proposal No. 2 was approved.

<u>Proposal No. 3</u>: Advisory vote on the compensation paid to the Company's named executive officers.

---

| | | | |
|:---|:---|:---|:---|
| | **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Abstained</u>** |
| Non-binding vote on the compensation of the Company's named executive officers | 87,521,620 | 4,202,883 | 1,486,826 |

---

Broker Non-Votes: 32,137,064

Proposal No. 3 was approved.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 4, 2026

---

| | |
|:---|:---|
| **Biohaven Ltd.** | **Biohaven Ltd.** |
| By: | /s/ Matthew Buten |
|  | Matthew Buten |
|  | Chief Financial Officer |

---